FRC Logo
🔹
🔹
•

News

Latest Market News

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Bristol-Myers Squibb Company Stock AnalysisComprehensive stock analysis for Bristol-Myers Squibb Company (BMY) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisBMY

Bristol-Myers Squibb Company

BMY
Stock Price
$0.00
Updated 07:00 PM
Sign In
  • Phase 1 · Company Overview
  • Phase 2 · FRC Research
  • Phase 3 · Financial Data
  • Phase 4 · Peer Comparison
  • Phase 5 · Ownership & News
BMY$0.00
Home🔹Stocks🔹Bristol-Myers Squibb Company

Bristol-Myers Squibb Company

BMY•NYSE

Bristol-Myers Squibb Company

BMY•NYSE
Mkt Cap$95.80B
Sentiment

Bristol-Myers Squibb Company

BMY
Stock Price
$0.00
Updated 07:00 PM
Sign In
  • Phase 1 · Company Overview
  • Phase 2 · FRC Research
  • Phase 3 · Financial Data
  • Phase 4 · Peer Comparison
  • Phase 5 · Ownership & News
BMY$0.00
Phase 1 · Company Overview
1

Step 1: Overview

What the company does, where it operates, and who runs it.

Overview for Bristol-Myers Squibb Company

Industry:Drug Manufacturers - General
Sector:Healthcare
CEO:Christopher S. Boerner
Description:Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Address:430 East 29th Street, Princeton, NY, US
2

Step 2: Infographics

Visual summary of the business at a glance.

Phase 2 · FRC Research
3

Step 3: Media

Videos and interviews covering the company.

Phase 3 · Financial Data
4

Step 4: Stock Data

Price chart, volume, and trading data.

BMY Stock Price

5

Step 5: Fair Value

What FRC thinks the stock is worth vs. the current price.

6

Step 6: Financial Ratios

Profitability, returns, valuation, and leverage ratios.

7

Step 7: Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

8

Step 8: Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

9

Step 9: Financial Statements

Income statement, balance sheet, and cash flow statements.

Phase 4 · Peer Comparison
10

Step 10: Comparables

List of peer companies in the same industry.

Phase 5 · Ownership & News
12

Step 12: Institutional Ownership

Which funds and firms own the stock.

13

Step 13: Insider Trading

Recent buying and selling by company executives.

14

Step 14: Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

15

Step 15: News

Latest headlines and market coverage.

News

Latest Market News

News

Latest Market News